home > pmps > winter 2017 > out with the old
Pharmaceutical Manufacturing and Packing Sourcer

Out With the Old

What a year 2016 has been. The Year of the Monkey certainly lived up to the mischievous nature of the animal with 2016 having been possibly the most unpredictable year in living memory. If someone had placed a £1 bet a year ago on Leicester City winning the Premier League, the UK voting to leave the EU and Donald Trump being elected as the next president of the US, then they would have picked up £4.5 million from the bookmaker!

What Will 2017 Bring?

The next year is sure to see the repercussions of Brexit continuing to cause unrest within the pharma industry. The nature of the relationship between Britain and the EU will not be decided in 2017, but investment strategies will most definitely be influenced by the inevitability of changes to business and regulatory practices between the two and, of course, the question over the freedom of movement of workers within the EU.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Robert Harris is Chief Technical Officer at Juniper Pharma Services and PMPS Industry Advisor
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events


15-17 July 2020, Javits Center NYC

More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement